Stifel raised the firm’s price target on Argenx (ARGX) to $1,248 from $1,028 and keeps a Buy rating on the shares. The firm “refreshed diligence” on many companies within its biotechnology coverage universe and made a number of model, estimate and price target changes in a 2026 look ahead note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $910 from $800 at UBS
- Argenx price target raised to $1,100 from $925 at JPMorgan
- Argenx price target raised to $1,110 from $1,070 at Morgan Stanley
- Argenx downgraded to Peer Perform from Outperform at Wolfe Research
- argenx SE Shareholders Approve Remuneration Policy at Extraordinary Meeting